Invasive Trichosporon infection in solid organ transplant patients: a report of two cases identified using IGS1 ribosomal DNA sequencing and a review of the literature. Issue 1 (3rd January 2014)

• Record Type: Journal Article
• Authors: Almeida Júnior, J.N.; Song, A.T.W.; Campos, S.V.; Strabelli, T.M.V.; Del Negro, G.M.; Figueiredo, D.S.Y.; Motta, A.L.; Rossi, F.; Guitard, J.; Benard, G.; Hennequin, C.
• Is Part Of: Transplant infectious disease. Volume 16:Issue 1(2014)
• Page Start: 135
• Page End: 140
• Publication Date: 2014-01-03
• Subjects: Transplantation of organs, tissues, etc -- Complications -- Periodicals; Communicable diseases -- Periodicals; Infection -- Periodicals; 617.01
• DOI: 10.1111/tid.12179
• Languages: English
• ISSNs: 1398-2273

Abstract

<abstract abstract-type="main" id="tid12179-abs-0001"> <title>Abstract</title> <p> <italic>Trichosporon</italic> species are rare etiologic agents of invasive fungal infection in solid organ transplant (SOT) recipients. We report 2 well‐documented cases of <italic>Trichosporon inkin</italic> invasive infection in SOT patients. We also conducted a detailed literature review of <italic>Trichosporon</italic> species infections in this susceptible population. We gathered a total of 13 cases of <italic>Trichosporon</italic> species infections. Any type of organ transplantation can be complicated by <italic>Trichosporon</italic> infection. Bloodstream infections and disseminated infections were the most common clinical presentations. Liver recipients with bloodstream or disseminated infections had poor prognoses. Although the most common species was formerly called <italic>Trichosporon beigelii</italic>, this species name should no longer be used because of the changes in the taxonomy of this genus resulting from the advent of molecular approaches, which were also used to identify the strains isolated from our patients. Antifungal susceptibility testing highlights the possibility of multidrug resistance. Indeed, <italic>Trichosporon</italic> has to be considered in cases of breakthrough infection or treatment failure under echinocandins or amphotericin therapy. Voriconazole seems to be the best treatment option.</p> </abstract>